An observational study in Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure, sponsored by Bayer. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Heart Failure by Bayer — 6 open to participants now, 7 under way, 2 of them phase 3. Heart Failure · Bayer.
Among the 47 studies in Heart Failure by Bayer, this one is the 9th largest by enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, and was the 41st registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 47 studies in Heart Failure by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages up to 18
Bayer · Sites in Korea, Republic of
Ages 19+
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages 6 mo–17 yrs
Bayer · Sites in Austria, Belgium, Croatia and 14 more countries
Ages 18+
Bayer · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 604 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 62 across the 33 interventional studies, 1,175 across the 14 observational. Of the 40 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
2 of the studies in Heart Failure by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07379840BayerA Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea | 2026-12-31 |
| NCT06148935BayerAn Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 47 studies in Heart Failure by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and even death.
The study drug, vericiguat, is already approved for doctors to prescribe to people with worsening of heart failure with chronic HFrEF in India.
Vericiguat increases the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels, allowing more blood to flow through. As a result, the heart is able to pump better.
The participants in this study are already receiving treatment with vericiguat as part of their regular care from their doctors. There is currently limited real-world data on the use of vericiguat. Furthermore, discussing whether vericiguat treatment should start early in people with heart failure can help doctors manage these people better.
The main purpose of this study is to collect information about how well vericiguat works and how safe it is in Indian people with chronic HFrEF who have experienced worsening heart failure. To do this, researchers will collect the following information:
The data will come from the participants' hospital, medical and electronic healthcare records. Data collected will be from Indian people with chronic HFrEF who started taking vericiguat between September 2022 and August 2023.
Researchers will track participants' data and will follow them until Feb 2024. In this study, only available data from routine care are collected. No visits or tests are required as part of this study.
The primary source of data is hospital medical records. The electronic health records or physical records of patients with HFrEF who were managed with Vericiguat will be screened to obtain the relevant baseline and follow-up data. Such records will be collected from 15 participating sites in India.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
New users who have been initiated on Vericiguat between 01 Sep 2022 and 31 Aug 2023 in 15 Sites in India
Drug: Vericiguat (Verquvo, BAY1021189)
Prescibed as per local label
Descriptive measurement of baseline clinical characteristics of patients initiated on Vericiguat
Clinical characteristics include demographics, concomitant medication, medical history and surgical history, history of hospitalization, N-Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) levels
Time frame: At baseline
Descriptive measurement of baseline treatment patterns of patients initiated on Vericiguat
Time frame: At baseline
Description of the use of medications of interest (yes/no) before/after initiation of Vericiguat
Includes description of prescribed amount of medications of interest in respective observation periods
Time frame: Up to 12 months
Descriptive measurement of titration patterns
Includes starting dose, up-titration / down-titration (yes/no), time until target dose
Time frame: Up to 12 months
Descriptive measurement of treatment discontinuation
Includes descriptive analysis of number of patients who have discontinued treatment, time points of discontinuation, reasons for discontinuation (Symptomatic hypotension, syncope)
Time frame: Up to 12 months
Number of patients with hospitalizations due to heart failure after Vericiguat initiation
Time frame: Up to 12 months
Cardiovascular mortality rate
Time frame: Up to 12 months
Composite of heart failure hospitalization and cardiovascular mortality
Time frame: Up to 12 months
Number of patients with symptomatic hypotension or syncope after Vericiguat initiation
Time frame: Up to 12 months
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Sep 2026, 12 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2026 → Sep 2026 and completion Jun 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.